NPM1 and leukemia: Furthermore, since NPM1-mutated leukemia cells are associated with increased CD33 expression [72], CD33 antibodies like gemtuzumab ozogamicin (GO) could be a targeted therapy for those NPM1-mutated patients with high CD33 expression.